论文部分内容阅读
尿激酶用于治疗玻璃体出血有的获得了令人鼓舞的效果(Forrester et al 1974),有的则结果令人失望(Cleary er al 1974)。病例的选择差不多是相同的,如铅尿病者为最多,其他有高血压、血管意外及过量用抗凝剂引起的玻璃体出血。是什么因素致使有的治疗成功有的则无效? 玻璃体出血的结局,特别是在病理学方面,很少了解。常见到的白内障摘除术中发生的位于玻璃体表面的出血,呈亮红色的血凝块,于几周内即可消失。玻璃体下或视网膜前的出血则仍保
The encouraging results have been obtained with urokinase for the treatment of vitreous hemorrhage (Forrester et al 1974), while others are disappointing (Cleary et al 1974). Case selection is almost the same, such as the largest number of people with lead and other high blood pressure, vascular accident and excessive use of anticoagulants caused by vitreous hemorrhage. What factors make some successful treatment is ineffective? The outcome of vitreous hemorrhage, especially in pathology, is poorly understood. Bleeding on the vitreous surface, a bright red blood clot that occurs most commonly during cataract extraction, can disappear within a few weeks. Vitreous or retinal bleeding is still preserved